ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Biohaven Completes Randomization in Phase 2/3 Trial in Spinocerebellar Ataxia
August 08, 2017Biohaven Pharmaceutical has commenced dosing of all 141 randomized patients with spinocerebellar ataxia (SCA) in its Phase 2/3 trial of trigriluzole (previously known as BHV-4157). Trigriluzole has received both Orphan Drug Designation and Fast Track Desi
Pharma Sources Insight January 2025
